We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 495

Insight into recent PRB decisions on pharmaceutical biotech inventions
  • Peksung Intellectual Property Ltd
  • China
  • December 11 2015

The Patent Reexamination Board (hereinafter referred to as the PRB) is an organization under the SIPO (State Intellectual Property Office) of China


News and cases from China: August - September 2015
  • Rouse
  • China
  • October 29 2015

Recently, the National Copyright Administration issued Implementing Measures for the Copyright Administrative Penalties (Revision Draft for Comment


吉利德丙肝药sovaldi最新专利申请遭中国拒绝
  • Beijing Sanyou Intellectual Property Agency Ltd
  • China
  • September 11 2015

根据美国游说组织I-MAK消息吉利德公司的重磅级丙肝药物专利申请遭到中国SIPO拒绝这是在I-MAK提出专利授予前异议后做出的决定I-MAK还联合其他公益性组织对该药物在欧盟印度和俄罗斯等其他市场的专利申请发起挑战索非布韦核心专利此前已经在印度和埃及遭到拒绝


Experimental use exemption of patent infringement ̶ a brief comparison of China and the United States
  • Peksung Intellectual Property Ltd
  • China, USA
  • February 3 2015

Generally, the purpose of a patent is to award the patentee a limited market monopoly for disclosing his invention to the public. Experimental use of


Patent protection for medical uses and relevant judicial practice in China
  • Wan Hui Da Law Firm & Intellectual Property Agency
  • China
  • June 18 2014

The Supreme People's Court (hereinafter refers to as SPC) recently announced "2013 Top Ten Innovative Intellectual Property Cases of Chinese Court"


China’s Patent Re-Examination Board says pharmaceutical salts not patentable over pure compounds
  • Greenberg Traurig LLP
  • China
  • August 14 2013

In July 2013, the Patent Re-Examination Board of China's State Intellectual Property Office invalidated the U.S. biotech company, Gilead Sciences'


China newsletter - summer 2013
  • Greenberg Traurig LLP
  • China, Macau
  • July 17 2013

For the purpose of fully implementing the spirit of the Eighteenth National Congress of the Communist Party of China and attracting more foreign


Life sciences: 2013 legal developments you need to know about
  • Mayer Brown LLP
  • China, European Union, France, USA
  • July 16 2013

This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. The developments include the Supreme Court


Changing trends in patent protection for the pharma industry
  • Heskia - Hacmun Law Firm
  • China, India, Israel
  • June 6 2013

This April India's Supreme Court oversaw a high profile case involving Novartis' patent application for Glivec, a cancer-battling medication


Insights on drafting pharmaceutical patents from the “Supreme People’s Court’s Annual Report of Intellectual Property Cases”
  • King & Wood Mallesons
  • China
  • May 31 2013

In April 2013, the Supreme People's Court ("SPC") issued the"Supreme People's Court's Annual Report of Intellectual Property Cases", in which the SPC